Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice
about
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesClinical development of Ebola vaccinesChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the BrainA viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.Characterization of a single-cycle rabies virus-based vaccine vector.Nonreplicating vectors in HIV vaccines.Development of replication-competent viral vectors for HIV vaccine delivery.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primatesA vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA VirusesSignificant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectorsFirst-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.A vesiculovirus showing a steepened transcription gradient and dominant trans-repression of virus transcription.Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.Lessons learned from HIV vaccine clinical efficacy trials.Ebola virus disease candidate vaccines under evaluation in clinical trials.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsRecombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cellsNovel viral vectors in infectious diseases.Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityEvolutionarily stable attenuation by genome rearrangement in a virus.Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
P2860
Q21131585-7DC07B8D-E483-48AC-9FE4-49C50200D3CAQ26775792-E81D57F5-420F-4B1D-AB59-6AE2D283B1DDQ28223031-3EF4AC66-8BB5-4FF9-9DB2-DBC8688823AAQ30370147-30A2DE6C-E0DF-4A6C-B3E8-1DDC09846B09Q30385999-B4EE8CE6-CD59-40CC-8EF5-406B46A69531Q30389455-AB46DA77-1D39-483A-BC17-1BFDE8E1A6DAQ33676502-55D3CF54-E19E-4991-8733-215DCCD50425Q33693891-1290BF4E-38E3-4A73-A6BC-E477D8C03FEBQ33694226-722895C3-FE61-4B7B-94F2-12B24C115504Q33725635-459303A2-6A14-4EEC-B4D9-FFB9BE0874DDQ33743852-16DDEF62-F58F-4372-B387-521991A7C216Q33832168-B01E17DE-05BE-465B-8017-6DFF6F928471Q33964081-68E16361-5882-44A5-86FE-B2B1776B4776Q34172295-9BB4B2B5-50A6-4CE7-8174-DA258C0BA5A4Q34262131-7FF4A97B-B440-4687-924C-5F4BA8903378Q34296144-60EDF285-0541-4814-A9F6-EFDE131850F6Q34806497-0DC8C52E-0FCC-47BF-9E06-0D1E5B75B642Q35076961-062BDC9E-085A-40D1-8F50-BB7FB6BF9B7BQ35760520-A4F8069A-4BC6-42A7-A805-9E44F74E2ECEQ35858437-5455B18E-C35C-4513-AE71-44417B0FFDC0Q36007614-C114617C-B284-486B-8208-32A08A993F51Q36043290-7667A500-C5FF-4E08-A4E4-482443F20028Q36172158-FF81A98B-FF8C-4540-AB3A-C8DAB8891391Q36239796-1C93A396-42A5-45B6-B5E8-5AADC25A2FF6Q36898706-0EF59B32-3C37-4A9E-8FA5-CF3D7C467C7AQ37107609-126F949D-2479-4B4F-B779-1639E3F584C5Q37354600-E7918C5C-0677-48AF-8C75-47C09C54B42FQ37355979-9E369401-8A33-40CB-B7D0-29A65DB5D10FQ37373616-FDAC07D4-60BA-47B6-9F0B-AC0A9D55501AQ37714030-5DF16D2F-FAA5-4CF2-979A-9902343D17D0Q37724091-F285A87E-51F0-4D9E-AF6D-631E883D740DQ38830109-01A5AB28-E2B0-4BD0-8BD6-E9FF23D7CACCQ38886667-016017EB-AE1D-482E-BFE4-5E1DBEE62FC4Q39294255-F8D4ABE8-DE35-4236-A626-8FA7F0CE0B01Q39776032-80FD2DC7-EF0F-443F-AD4C-28EDF570A91EQ40059020-57F01A1B-9116-42DC-AA7D-2B8887885CFCQ40619713-CFC553E4-0C83-44C1-844B-34A3D0BE7081Q41770092-D5771A00-B5B4-4B35-AE5F-AE99AF72F2C8Q42288506-7BA868A9-E53F-4220-AFB8-069D7B003A87Q44106241-AF195994-5E25-4084-9EC7-297A9F310688
P2860
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@ast
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@en
type
label
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@ast
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@en
prefLabel
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@ast
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@en
P2093
P2860
P356
P1433
P1476
Attenuation of recombinant ves ...... nhances immunogenicity in mice
@en
P2093
Cheryl Kotash
David Cooper
David K Clarke
Irene Yurgelonis
J Erik Johnson
John W Coleman
Kevin J Wright
Margaret Lee
Priscilla C Calderon
P2860
P304
P356
10.1128/JVI.01515-07
P407
P50
P577
2007-10-17T00:00:00Z